Goodrx Holdings, Inc. (GDRX) Stock Price & Analysis
Goodrx Holdings, Inc. (GDRX) rose 0.76% to USD 2.65 as of June 10, 2026 at 00:39 UTC, according to Nexqual real-time market data.
GDRX last closed at USD 2.63; the session ranged USD 2.57–2.77 on volume of 1,557,313 shares. Market capitalization is $897.49M, with a 52-week range of USD 1.77–5.81 (NMS). Source: Nexqual, June 10, 2026 at 00:39 UTC.
Key Statistics (as of June 10, 2026 at 00:39 UTC)
| Price | USD 2.65 |
|---|---|
| Change | ▲ 0.76% (up) |
| Previous Close | USD 2.63 |
| Open | USD 2.67 |
| Day Range | USD 2.57 – 2.77 |
| 52-Week Range | USD 1.77 – 5.81 |
| Volume | 1,557,313 shares |
| Market Cap | $897.49M |
| Exchange | NMS |
Technical Analysis (GDRX)
Nexqual's technical model rates GDRX "NEUTRAL" based on 3 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 00:39 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 49.79 (neutral) |
| vs SMA50 | Above (USD 2.47) |
| MACD | 0.07 (positive) |
Analyst Ratings (GDRX)
Wall Street analysts rate GDRX "None" based on 13 analysts, with a mean price target of USD 3.18 (range USD 2.25–4), per Nexqual as of June 10, 2026 at 00:39 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 3.18 |
| High Target | USD 4 |
| Low Target | USD 2.25 |
| Buy / Hold / Sell | 5 / 8 / 2 |
Earnings (GDRX)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 0.08 |
| Revenue Estimate | $193.16M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.07 vs est 0.07 ▼ miss |
| 2025-12-31 | USD 0.09 vs est 0.09 ▼ miss |
| 2025-09-30 | USD 0.08 vs est 0.09 ▼ miss |
| 2025-06-30 | USD 0.09 vs est 0.1 ▼ miss |
Source: Nexqual, June 10, 2026 at 00:39 UTC.
Financials & Fundamentals (GDRX)
| Total Revenue | $787.89M |
|---|---|
| Revenue Growth (YoY) | -4.40% |
| Gross Margin | +91.83% |
| Operating Margin | +7.22% |
| Profit Margin | +2.61% |
| ROE | +3.22% |
| Debt / Equity | 87.04 |
| Current Ratio | 1.47 |
| Total Cash | $235.71M |
| Total Debt | $541.35M |
| Free Cash Flow | $84.62M |
Source: Nexqual, June 10, 2026 at 00:39 UTC.
Financial Health Score (GDRX)
Nexqual rates Goodrx Holdings, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:39 UTC.
| Growth | Mixed — Revenue +0.6% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 92%, operating 7% |
| Balance Sheet | Mixed — $236M cash vs $541M debt |
| Cash Flow | Solid — FCF $85M, 11% margin |
| Efficiency | Weak — ROE 3%, ROA 3.5% |
Ownership (GDRX)
| Insider Ownership | +13.11% |
|---|---|
| Institutional Ownership | +56.68% |
| Shares Outstanding | 104.71M |
| Float | 91.49M |
| Short % of Float | +11.66% |
Source: Nexqual, June 10, 2026 at 00:39 UTC.
Leadership (GDRX)
Goodrx Holdings, Inc. is led by Wendy Barnes (age 52), President, CEO & Director, per Nexqual as of June 10, 2026 at 00:39 UTC.
| President, CEO & Director | Wendy Barnes (age 52) |
|---|---|
| Co-founder & Director | Douglas Joseph Hirsch (age 54) |
| CFO & Treasurer | Christopher A. McGinnis (age 54) |
| Chief Strategy & Operations Officer | Justin Fengler |
| Chief Technology Officer | Nitin Shingate |
Major Backers & Investors (GDRX)
Notable institutional backers of Goodrx Holdings, Inc. include LSV Asset Management, Ameriprise Financial, Inc., Silver Lake Group, LLC, according to Nexqual as of June 10, 2026 at 00:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| LSV Asset Management | 4.76% |
| Ameriprise Financial, Inc. | 4.26% |
| Silver Lake Group, LLC | 3.37% |
| Renaissance Technologies | 3.11% |
| Petrus Trust Company, LTA | 2.96% |
| Prescott Group Capital Management, L.L.C. | 2.01% |
| Pacer Funds Trust-Pacer US Small Cap Cash Cows 100 ETF | 0.74% |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Targeted Value Portfolio | 0.51% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 14.22% |
| Dimensional Fund Advisors | 2.34% |
Source: Nexqual, June 10, 2026 at 00:39 UTC.
From Goodrx Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Our Technology The key elements of our technology include: • Proprietary Pricing Engine: Our price ingestion technology enables us to link with multiple sources spanning the healthcare industry.
- Our proprietary technology enables us to aggregate prescription pricing data points from sources spanning the healthcare industry.
- Our broad set of long-term relationships across the industry, combined with our proprietary platform, allows us to present highly competitive prices to consumers.
- Our proprietary technology enables us to combine prices from multiple PBMs and other industry sources and display it on a single consumer interface.
Partnerships
- In 2025, we partnered with select pharmacies to offer our brand medication savings solution, RxSmartSaver+ , to their consumers for a monthly or annual fee. • Condition-Specific Subscriptions: We first launched condition-specific subscriptions in 2025.
- In 2025, we continued to grow our consumer direct pricing and announced a collaboration with a pharmaceutical manufacturer to offer eligible patients nationwide two of the most in-demand GLP-1 medications at a significantly lower cash price through our platform.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AMWL | American Well Corporation | USD 8.5 | ▼ 1.39% |
| FROG | JFrog Ltd. | USD 81.26 | ▼ 3.26% |
| ASAN | Asana, Inc. | USD 7.54 | ▼ 3.83% |
| NCNO | nCino, Inc. | USD 15.52 | ▲ 4.02% |
| GTM | ZoomInfo Technologies Inc. | USD 2.77 | ▼ 7.05% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:39 UTC. This page is informational and not investment advice.